Cash, cash equivalents, and short-term investments were $84.8 million as of March 31, 2025. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of March 31, 2025, will enable the Company to fund cash flow requirements into the first quarter of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- INZY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Promising Potential of INZ-701 in Treating ENPP1 Deficiency Drives Buy Rating for Inozyme Pharma
- Inozyme announces JBMR Plus publication on ENPP1 deficiency
- Buy Rating on Inozyme Pharma: Promising Potential of INZ-701 and Market Opportunity